| Discovery Labs: Small Biotech With Multiple Prime Time Catalysts Without a doubt, this past year the biotech industry has been characterized by companies who’ve found ways to persevere past adversity, overcoming financial and economic downturns to bring in hefty profits for shareholders who took comfort in the saying, “patience is a virtue”. In order to understand this concept, we are going to highlight some of the companies we’ve profiled in the past in order to prove that being small does not translate to an inability to stand tall amongst the big boys. Yes, ladies and gentlemen, comebacks do happen in the game of investments, and they are no different than your favorite sporting hero scoring a game winner. Amidst buyout/partnership rumors from the top drug makers in the world, of the likes including Johnson & Johnson (NYSE:JNJ), Merck & Co. (NYSE:MRK) and Pfizer (NYSE:PFE), Discovery Laboratories (DSCO) is stepping up to the plate with some major upcoming company developments that could make this the next small cap home run play. Among the upcoming binary events: completion of BAT during May as the last step for FDA resubmission on its flagship product, phase 2 results for Acute Respiratory Failure in June, initiation of phase 2a trial for Cystic Fibrosis in 3Q10, and FDA submission of the flagship product, Surfaxin in the treatment of ARDS, during 1Q11. Make no mistake about it, there is serious room for growth as this 70M market cap company and Surfaxin are tapping into a $1.8 billion dollar market opportunity for Acute Respiratory Distress Syndrome, of which currently there are no drugs approved for treatment. What makes this story even more compelling is that Discovery has met and received response letters from the FDA a total of three times, all with minor requirements that have since been met and completed. As a well-capitalized company paired with strong fundamental and technical chart breakout potential, it is undeniable that its re-emergence as a healthy NASDAQ listed company is right around the corner.Complete Story » seekingalpha.com |
When a Heart Risk Runs in the Family Hundreds of thousands of Americans die of sudden cardiac arrest each year, an occurrence that can run in families. Now, genetic testing can help pinpoint the cause of death to save relatives. online.wsj.com |
Sanofi Prepares Bid for Genzyme as Need to Diversify Portfolio Increases The Burrill Report submits: By Michael FitzhughSanofi-Aventis (SNY), France's largest pharmaceutical, is expected to make a formal bid of as much as $18.7 billion for the U.S. biotech giant Genzyme (GENZ) and its portfolio of rare-disease therapeutics, which could help staunch its losses as low-priced generic competition erodes its sales. Complete Story » seekingalpha.com |
Neogen CEO Discusses F1Q2011 Results - Earnings Call Transcript Neogen Corporation (NEOG)F1Q2011 Earnings Call TranscriptSeptember 23, 2010 11:00 am ETComplete Story » seekingalpha.com |
Challenge to Health Law Proceeds A federal judge in Florida refused to dismiss a lawsuit by 20 states that challenges the constitutionality of the Obama administration's health-care overhaul. online.wsj.com |